Methylmalonic Acid: The Test That Catches B12 Deficiency Earlier

The methylmalonic acid (MMA) test is a blood (or urine) test that answers a question the standard vitamin B12 test cannot: are your cells actually getting enough B12 to do their job? A serum B12 level tells you how much of the vitamin is floating in your bloodstream. MMA tells you whether the B12-dependent machinery inside your cells is running or stalling — and it starts rising before the standard test drops below the "normal" line. That makes it the closest thing medicine has to an early-warning system for B12 deficiency.

This matters because B12 deficiency is common, sneaky, and — if it reaches the nervous system — only partially reversible. Millions of people sit in the "gray zone" of the standard test: tired, tingling, foggy, told their B12 is "fine." For many of them, an MMA test is the second look that settles the question for well under $100. This article explains what MMA measures, who should consider it, how to read the result (including the one big false-positive trap: kidney function), and what honest treatment and retesting look like.

Table of Contents

  1. The Problem With the Serum B12 Test
  2. What MMA Actually Measures
  3. MMA vs. Homocysteine
  4. Who Should Consider the Test
  5. Reading Your Results
  6. The Kidney Caveat: The Biggest False Positive
  7. The Neurological Stakes
  8. Getting Tested: Ordering, Cost, Preparation
  9. Treating and Retesting
  10. Research Papers and References
  11. Connections

The Problem With the Serum B12 Test

The standard serum B12 test measures the total amount of vitamin B12 in your blood. The problem is that most of that total is not available to your cells. Roughly 70–80% of circulating B12 rides on a carrier protein called haptocorrin, which cells cannot take up; only the remaining fraction, bound to transcobalamin (so-called "active B12" or holotranscobalamin), can actually be delivered into tissues. Two people with the same total B12 number can have very different amounts of usable vitamin, and shifts in the carrier proteins — from pregnancy, oral contraceptives, liver disease, or ordinary genetic variation — can move the total up or down without changing what cells receive.

Then there is the gray zone. Most labs flag serum B12 as "low" only below roughly 200 pg/mL (≈148 pmol/L). But a large body of research shows that people with values between roughly 200 and 400 pg/mL — officially "normal" — are frequently deficient at the tissue level, with elevated metabolic markers and real symptoms. In the landmark case series by Lindenbaum and colleagues in the New England Journal of Medicine, a substantial share of patients with outright neurologic disease from B12 deficiency had serum values that were low-normal rather than frankly low — and about 28% had no anemia and no enlarged red cells at all, the two findings doctors are traditionally taught to wait for.

The practical rule that follows: a "normal" B12 result in a person with suggestive symptoms deserves a second look. Numbness or tingling, balance problems, burning feet, unexplained fatigue, brain fog, a sore or smooth tongue, or unexplained mood and memory changes — with a serum B12 anywhere under about 400 pg/mL — is exactly the situation the MMA test was made for. Functional markers like MMA catch the deficiency the screening test misses.

What MMA Actually Measures

Here is the biochemistry in one paragraph. When you metabolize certain fats (odd-chain fatty acids and cholesterol fragments) and certain amino acids (valine, isoleucine, methionine, threonine), the breakdown products funnel into a molecule called methylmalonyl-CoA. To finish the job, an enzyme called methylmalonyl-CoA mutase must convert methylmalonyl-CoA into succinyl-CoA, which feeds your cells' energy cycle. That enzyme has an absolute requirement for vitamin B12 (in its adenosylcobalamin form) as a cofactor. No B12, no conversion — methylmalonyl-CoA piles up at the blocked step, the cell hydrolyzes the excess into methylmalonic acid, and the MMA spills out into the blood and urine, where a lab can measure it.

That is why MMA is called a functional marker: it does not measure how much B12 you have, it measures whether a specific B12-dependent reaction is failing inside your cells. In the classic diagnostic studies by Allen, Stabler, Savage, and Lindenbaum, MMA was elevated in more than 98% of patients with clinically confirmed B12 deficiency — including many whose serum B12 sat in the normal range. Because the metabolite backs up as soon as tissue supplies run short, MMA typically rises weeks to months before the serum level falls below the lab cutoff, which is the entire case for using it as an early-detection test. (Very high MMA in an infant is a different matter entirely — a rare inherited enzyme defect called methylmalonic acidemia, caught by newborn screening — and is not what this article is about.)

MMA vs. Homocysteine

B12 works as a cofactor in exactly two human enzymes, and each one gives us a lab marker. The first is methylmalonyl-CoA mutase, described above — its failure raises MMA. The second is methionine synthase, which recycles homocysteine back into methionine and needs both B12 (as methylcobalamin) and folate to run. Its failure raises homocysteine. So in true B12 deficiency, both markers typically rise together.

The reason to know both is that they fail differently, and the pattern localizes the problem:

Of the two, MMA is the more specific B12 marker: homocysteine rises with folate deficiency, B6 deficiency, kidney disease, hypothyroidism, smoking, and age, while an elevated MMA has a much shorter list of alternative explanations (kidney function being the big one — see below). Many clinicians order the pair when the picture is murky; if only one test is being added to a workup, MMA is usually the one. The site's homocysteine article covers that marker's own story, including its cardiovascular associations.

Who Should Consider the Test

An MMA test earns its cost wherever B12 deficiency is more likely than average, or where the standard test has already returned an ambiguous answer. The groups below account for most real-world cases:

Reading Your Results

Serum MMA. Reference intervals vary by laboratory and method, but most labs flag serum MMA above roughly 0.27 to 0.40 µmol/L (270–400 nmol/L) — treat the exact cutoff on your report as the one that counts. As a rough guide used in the research literature: values just above the cutoff are borderline and worth repeating or corroborating; values above about 0.75 µmol/L are strongly suggestive of true B12 deficiency in a person with normal kidney function. Mild elevations become more common with age, so a single borderline number in an older adult is a prompt for confirmation, not a verdict.

Urine MMA. Some laboratories (including several direct-to-consumer services) measure MMA in urine, normalized to creatinine. Urine MMA tracks serum MMA well, requires no blood draw, and is less distorted by mild kidney impairment, which makes it a reasonable screening alternative — though serum remains the better-studied standard, and any surprising urine result deserves serum confirmation.

What lowers MMA. B12 itself. If you started B12 supplements before testing, even a genuinely deficient person's MMA can already be normalizing — the test reads clean because treatment is working. For a clean diagnostic answer, test before supplementing, or interpret a normal result on supplements as "treatment adequate" rather than "never deficient."

What a high MMA does not tell you. It flags that the B12 pathway is failing, not why. A confirmed elevation still needs a cause: dietary, autoimmune (pernicious anemia), drug-induced, surgical, or malabsorptive. And one condition can raise MMA without any deficiency at all — which brings us to the kidney.

The Kidney Caveat: The Biggest False Positive

MMA is cleared from the blood by the kidneys. When kidney function declines, MMA accumulates because it is being excreted more slowly, not because cells lack B12. Chronic kidney disease is by far the single largest source of false-positive MMA results, and it matters in practice because reduced kidney function and B12 deficiency concentrate in the same population: older adults, people with diabetes on metformin, people with hypertension.

The Neurological Stakes

The reason to catch functional B12 deficiency early — the reason this test exists — is what late deficiency does to the nervous system. B12 is required to maintain myelin, the insulation around nerve fibers. Prolonged deficiency produces subacute combined degeneration: demyelination of the spinal cord's dorsal columns (which carry vibration and position sense) and corticospinal tracts (which carry movement commands). It announces itself as tingling and numbness in the feet and hands, a strange loss of balance in the dark, clumsiness, stiff or weak legs — and, in parallel, as memory problems, depression, irritability, or in severe cases frank dementia and psychosis.

Two facts give the condition its urgency. First, it does not wait for anemia: in the Lindenbaum series, about 28% of patients with neuropsychiatric disease from B12 deficiency had neither anemia nor macrocytosis, so a normal CBC offers no reassurance. Second, recovery is only partial once damage is established. Treatment reliably halts progression, and symptoms of weeks-to-months duration often improve substantially — but deficits that have persisted a year or more frequently leave permanent residue. The same injury caught at the "tingling toes and a high MMA" stage is fully preventable. That asymmetry — cheap test, irreversible endpoint — is the entire argument for testing early in anyone at risk.

There is also the folate-masking problem. Folic acid can substitute for B12 in red-blood-cell production but not in myelin maintenance. A person deficient in B12 who takes folic acid (or simply eats a fortified-grain diet, as most Americans do) can have their anemia corrected or prevented while the neurologic damage advances silently — the classic "masked" deficiency. In a fortification era, the old strategy of letting anemia reveal B12 deficiency is broken, which strengthens the case for functional markers like MMA in symptomatic people.

Getting Tested: Ordering, Cost, Preparation

Any clinician can order serum MMA; it is a routine send-out at worst. If your doctor declines or you prefer to self-pay, direct-to-consumer laboratory services in most U.S. states sell serum MMA for roughly $30–$90, and urine MMA kits exist in a similar range. Hospital-lab list prices can run several hundred dollars before insurance adjustment — ask for the cash price. Insurance generally covers the test when tied to a plausible indication (neuropathy, unexplained anemia, a borderline B12 result, long-term metformin use). All prices here are rough U.S. figures that vary by region and lab.

Preparation is minimal: fasting is not usually required, though some laboratories prefer a fasting sample — follow your lab's instructions. The one preparation rule that genuinely changes the answer: if you want a diagnosis, test before starting B12 supplements, because supplementation begins normalizing MMA within days. Pairing the test with a metabolic panel (for kidney function) and, when budget allows, homocysteine or holotranscobalamin gives the most interpretable picture in one draw.

Treating and Retesting

If MMA confirms deficiency, the treatment question is oral versus injection — and the evidence here is more reassuring than most patients expect. About 1% of a swallowed B12 dose absorbs by passive diffusion, needing no stomach acid and no intrinsic factor. That means high-dose oral B12 — 1,000 to 2,000 mcg daily — delivers enough even in pernicious anemia and after gastric surgery. In the randomized trial by Kuzminski and colleagues, 2,000 mcg oral daily corrected blood counts and normalized MMA at least as well as a standard injection schedule; a Cochrane review reached the same conclusion, while honestly noting the trials are few and small. So: the evidence favors oral therapy working for most people, with a limited evidence base rather than a mountain of it.

Injections still have a place: significant neurologic deficits (where rapid, guaranteed repletion is worth it — typically several loading injections over the first weeks, then maintenance), severe symptomatic anemia, malabsorption so complete that adherence to daily pills is doubtful, or simply a patient who prefers a monthly shot to a daily tablet. Either route, the cause determines the duration: dietary deficiency can eventually be maintained by diet or modest supplements, while pernicious anemia and post-surgical deficiency need lifelong therapy.

Retesting is how you close the loop. MMA begins falling within about a week of adequate treatment and typically normalizes within a few weeks; homocysteine falls on a similar schedule. A sensible plan is to recheck MMA (with a blood count, if anemia was present) around 2–3 months after starting therapy. Interpreting the recheck is refreshingly binary: MMA that has fallen to normal confirms both the diagnosis and the adequacy of your dose; MMA that has not budged on verified supplementation means the elevation was never about B12 — look again at kidney function, consider SIBO, or (rarely, in the young) an inherited enzyme variant. Expect nerve symptoms to lag the labs: numbness and balance improve over 3–12 months, and the longer symptoms stood before treatment, the slower and less complete the recovery — one more argument for having tested early.

Research Papers and References

  1. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. The American Journal of Medicine. 1994;96(3):239–246.
  2. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Diagnosis of cobalamin deficiency I: usefulness of serum methylmalonic acid and total homocysteine concentrations. American Journal of Hematology. 1990;34(2):90–98.
  3. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. New England Journal of Medicine. 1988;318(26):1720–1728.
  4. Stabler SP. Vitamin B12 deficiency. New England Journal of Medicine. 2013;368(2):149–160.
  5. Carmel R. How I treat cobalamin (vitamin B12) deficiency. Blood. 2008;112(6):2214–2221.
  6. Devalia V, Hamilton MS, Molloy AM; British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. British Journal of Haematology. 2014;166(4):496–513.
  7. Wolffenbuttel BHR, Wouters HJCM, Heiner-Fokkema MR, van der Klauw MM. The many faces of cobalamin (vitamin B12) deficiency. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2019;3(2):200–214.
  8. Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. Blood. 1998;92(4):1191–1198.
  9. Vidal-Alaball J, Butler CC, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database of Systematic Reviews. 2005;(3):CD004655.
  10. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181.
  11. Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. The Journal of Clinical Endocrinology & Metabolism. 2016;101(4):1754–1761.
  12. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435.

Live PubMed Searches

  1. Methylmalonic acid and B12 deficiency diagnosis
  2. Methylmalonic acid and kidney function
  3. Oral versus intramuscular B12 replacement

Connections

Back to Table of Contents